INFI - Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Infinity Pharmaceuticals ([[INFI]] +4.8%) has provided an update on MARIO-275 Phase 2 study evaluating the benefit of adding eganelisib to Bristol-Myers' Opdivo (nivolumab) in platinum-refractory advanced urothelial cancer patients who are immuno-oncology therapy-naïve, over nivolumab monotherapy which is approved in this setting.The Independent Data Monitoring Committee determined that there was a favorable risk/benefit for patients after lowering the dose from 40mg twice daily to 30mg twice daily to reduce the reversible liver enzyme elevations.The company has completed the evaluation of the 49 patients enrolled in the study with encouraging safety, response rate and progression free survival data, including in patients with low levels of PD-L1 expression. Data will be presented at a major medical meeting in Q1 2021.Now the Company is planning a new registration-enabling study and will not re-open enrollment in MARIO-275.Infinity ended 2020 with ~$34.1M in cash and investments, and fund operations through 2021.

For further details see:

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer